Chronic Disease
Our work in Chronic Disease
-
Trends in the Price per Median and Mean Life-Year Gained Among Newly Approved Cancer Therapies 1995 to 2017
High and rising launch prices of new cancer drugs have raised American public stakeholder and policy concern. A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.
Categorized in -
Measuring Alzheimer’s Disease and Other Dementias in Diverse Populations Using Medicare Claims Data
The researchers examined how methods used for identifying dementia in administrative claims affected dementia incidence across racial/ethnic populations using a 100% sample of Medicare beneficiaries.
-
Longitudinal Analysis of Dementia Diagnosis and Specialty Care Among Racially Diverse Medicare Beneficiaries
The burden of Alzheimer’s disease and other dementias is rapidly growing. Researchers found vast majority of dementia patients don’t receive specialty diagnosis and care.
-
Using the Drug Pricing Netflix Model to Help States Tackle the Hep C Crisis
Researcher Neeraj Sood has explored innovative payment models as a strategy for government entities to be able to pay for lifesaving cures that could eradicate diseases like hepatitis C. Louisiana, with some input from Sood, has just implemented a modified version of a subscription model to pay for Hep C treatments.
-
Contribution Of Care Source To Cancer Treatment Cost Variation In The US Military Health System
Seth Seabury and colleagues examined how care received from military treatment facilities or purchased care in civilian facilities contributed to cancer treatment costs for patients.
Categorized in -
Don’t Let the New Kidney Health Initiative Fade from View
As a kidney doctor and health policy researcher, I am surprised that President Donald Trump’s initiative to remake kidney treatment has not gotten more attention. We need to keep paying attention because so much is at stake.
Categorized in -
Assessing the Preparedness of the Canadian Health Care System Infrastructure for an Alzheimer’s Treatment
A report on Canadian readiness to deal with new Alzheimer’s disease treatments co-authored by Jakub Hlávka found that average wait times could reach 28 months and that the most pressing issue is a lack of dementia specialists.
Categorized in -
Louisiana’s Prescription Drug Experiment: A Model for the Nation?
On July 22, the USC-Brookings Schaeffer Initiative for Health Policy will hosted a conference on Louisiana’s subscription model to expand access to Hepatitis C treatment for the state’s incarcerated and Medicaid patients with the infection.
Categorized in -
Impact of Early Initiation of Antihypertensive Medications for Patients with Hypertension or Elevated Blood Pressure
Initiating antihypertensive medications before experiencing a cardiovascular disease-related clinical event was associated with reduced risk of AMI, stroke and death for all hypertensive patients identified in the new guidelines.
Categorized in -
Book Review: Immunotherapy’s Promise
Jakub Hlávka reviews a new book on the future of cancer treatments that he writes “[offers] a hopeful account of medical research that could, one day, save even more lives.”
Categorized in